biostudies-literatureGalsky MDParker Institute for Cancer ImmunotherapyCancer Research Institute (CRI)Prostate Cancer Foundation (PCF)National Institutes of Health (NIH)NCI NIH HHSProstate Cancer FoundationParker Institute for Cancer Immunotherapy (PICI)National Institutes of HealthCancer Research Institute1463-1475https://www.ebi.ac.uk/biostudies/studies/S-EPMC11995007biostudies-literatureUnknown31(8)<h4>Purpose</h4>Current immune checkpoint therapies offer limited benefits for metastatic castration-resistant prostate cancer. Novel combinations may enhance immunotherapy efficacy.<h4>Patients and methods</h4>We conducted an open-label, noncomparative platform trial (NCT03835533) in metastatic castration-resistant prostate cancer to assess nivolumab-based combinations. The cohorts were as follows: (A) bempegaldesleukin 0.006 mg/kg and nivolumab 360 mg i.v. every 3 weeks; (B) stereotactic body radiotherapy 30 to 50 Gy, CDX-301 75 μg/kg s.c. for 5 days, poly-ICLC 1 mg intramuscularly weekly twice for 3 weeks, and nivolumab 480 mg every 4 weeks; and (C) CDX-301 75 μg/kg for 10 days, INO-5151 3 mg intramuscularly on lead-in day 8, day 1 of cycles 1 to 3, and then every 12 weeks, and nivolumaClinical cancer research : an official journal of the American Association for Cancer ResearchClinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer.PMC11995007P30 CA008748R35CA253175R35 CA253175Autio KAGraff JNFriedlander TWDensmore JWentzel KBoffo SSkolnik JYellin MJLaVallee TMDa Silva DMFong LFairchild JGalsky MDShotts KMSpasic MLata JBhardwaj NChen ROSubudhi SKO'Donnell-Tormey JHowes TRKeler TCabanski CRDugan UfalseClinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer.<h4>Purpose</h4>Current immune checkpoint therapies offer limited benefits for metastatic castration-resistant prostate cancer. Novel combinations may enhance immunotherapy efficacy.<h4>Patients and methods</h4>We conducted an open-label, noncomparative platform trial (NCT03835533) in metastatic castration-resistant prostate cancer to assess nivolumab-based combinations. The cohorts were as follows: (A) bempegaldesleukin 0.006 mg/kg and nivolumab 360 mg i.v. every 3 weeks; (B) stereotactic body radiotherapy 30 to 50 Gy, CDX-301 75 μg/kg s.c. for 5 days, poly-ICLC 1 mg intramuscularly weekly twice for 3 weeks, and nivolumab 480 mg every 4 weeks; and (C) CDX-301 75 μg/kg for 10 days, INO-5151 3 mg intramuscularly on lead-in day 8, day 1 of cycles 1 to 3, and then every 12 weeks, and nivoluma2025-01-01T00:00:00Z2025 Apr2026-06-01T20:42:25.069Z2025-07-03T03:04:20.374ZS-EPMC119950073996435210.1158/1078-0432.CCR-24-3693